Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramelteon and Escitalopram in MDD with Insomnia
NCT00642694Phase 3Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2007
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ramelteon in major depressive disorder (MDD) and Insomnia, sponsored by UT Southwestern Medical Center. Primary endpoint: Percentage of Remitters on IDS-C30 at 12 weeks. Started May 2007; status: terminated.
02
Drugs
ramelteon
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT00642694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642694.